Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team. Dr Rojkjaer will lead all clinical development strategy and execution and support the company’s efforts to identify opportunities to expand its pipeline of innovative targeted therapies for haematological cancers.
Dr Rojkjaer is a board-certified haematologist with more than 15 years of global and regional clinical development and medical affairs expertise in the biotech and pharma industries, and has extensive experience in the development of both biologics and small molecules in haematology and immunology. She joins Nordic Nanovector from Novartis Pharmaceuticals where she held the position of Global Clinical Program Head, Oncology Global Development. Her previous roles also include CMO at Molecular Partners (Switzerland), Vice President, Head of Clinical Development at Morphosys AG (Germany), and Head of Global Medical Affairs, Biopharmaceuticals and Director of Clinical Development, Hematology in the US for Novo Nordisk.
Dr Rojkjaer holds a medical degree from the University of Toronto and received board certification in both internal medicine and hematology.
Dr Rojkjaer commented: “I am delighted to join Nordic Nanovector at this exciting time in its development. The company’s lead candidate Betalutin® is demonstrating in clinical studies its potential to become an important new therapy for the treatment of NHL patients. Its technology is also providing multiple exciting new pipeline opportunities. I look forward to working with the management team and contributing to the future growth of the company.”
Luigi Costa, Chief Executive Officer, added: “I am very pleased to welcome Lisa to the team. She brings on board strong expertise in clinical development of novel cancer treatments, particularly in the field of haematology. Lisa’s knowledge and leadership will be key to the development of Betalutin® as well as to support the growth of Nordic Nanovector’s promising pipeline.”